ANIK — Anika Therapeutics Share Price
0.000.00%
Last trade - 00:00- $233.01m
- $177.38m
- $119.91m
- 78
- 57
- 15
- 48
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.51 | ||
| Price to Tang. Book | 1.61 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.84% | ||
| Return on Equity | -4.82% | ||
| Operating Margin | -4.25% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 130.46 | 147.79 | 156.24 | 120.79 | 119.91 | 112.5 | 122.31 | 0.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -41.92 | -39.34 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Directors
- Cheryl Blanchard PRE (56)
- Michael Levitz CFO (45)
- David Colleran EVP (49)
- Thomas Finnerty EVP (63)
- James Loerop EVP (57)
- Sheryl Conley IND (61)
- John Henneman IND (59)
- Raymond Land IND (76)
- Glenn Larsen IND (67)
- Stephen Richard IND (58)
- Jeffery Thompson IND (55)
- Susan Vogt IND (67)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 6th, 2018
- Public Since
- May 16th, 1985
- No. of Employees
- 357
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 14,645,596
- Address
- 32 Wiggins Ave, BEDFORD, 01730-2315
- Web
- https://anika.com/
- Phone
- +1 7814579000
- Contact
- Mark Namaroff
- Auditors
- Deloitte & Touche LLP
Upcoming Events for ANIK
Anika Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Anika Therapeutics Inc Earnings Release
Similar to ANIK
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Anika Therapeutics share price?
As of Today at 18:16 UTC, shares in Anika Therapeutics are trading at $15.91. This share price information is delayed by 15 minutes.
How has the Anika Therapeutics share price performed this year?
Shares in Anika Therapeutics last closed at $15.91 and the price had moved by -35.17% over the past 365 days. In terms of relative price strength the Anika Therapeutics share price has underperformed the S&P500 Index by -41.17% over the past year.
What are the analyst and broker recommendations for Anika Therapeutics?
The overall consensus recommendation for Anika Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Anika Therapeutics dividend yield?
Anika Therapeutics does not currently pay a dividend.
Does Anika Therapeutics pay a dividend?
Anika Therapeutics does not currently pay a dividend.
When does Anika Therapeutics next pay dividends?
Anika Therapeutics does not currently pay a dividend.
How do I buy Anika Therapeutics shares?
To buy shares in Anika Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Anika Therapeutics?
As of the previous close price of $15.91, shares in Anika Therapeutics had a market capitalisation of $233.01m.
Where are Anika Therapeutics shares listed?
Here are the trading details for Anika Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ANIK
What kind of share is Anika Therapeutics?
Based on an overall assessment of its quality, value and momentum Anika Therapeutics is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Anika Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Anika Therapeutics is $24.00. That is 50.85% above the last closing price of $15.91.
Analysts covering Anika Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.35 for the next financial year.
Find out moreWhat is the trend in the Anika Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Anika Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -35.5%.
As of the last closing price of $15.91, shares in Anika Therapeutics were trading -26.76% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Anika Therapeutics PE Ratio?
The Anika Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $15.91.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Anika Therapeutics?
Anika Therapeutics' management team is headed by:
- Cheryl Blanchard - PRE
- Michael Levitz - CFO
- David Colleran - EVP
- Thomas Finnerty - EVP
- James Loerop - EVP
- Sheryl Conley - IND
- John Henneman - IND
- Raymond Land - IND
- Glenn Larsen - IND
- Stephen Richard - IND
- Jeffery Thompson - IND
- Susan Vogt - IND